Alzheimer’s disease is a prevalent form of a neurodegenerative disease that leads to the loss of long-term memory, as well as impaired cognitive and speech functions, followed by death. A. Alzheimer – the German psychiatrist, first described the disease in 1907.
The remedy against illness has not yet been developed. Scientists create methods to identify early symptoms and determine the causes of the disease. But there has not been much success on this issue in world medicine.
It is established that people of advanced age from 60-65 years are subject to dementia. There are more than 26 million Alzheimer’s patients in the world. According to the forecasts of doctors, by 2050 the total number of patients may increase to 110 million.
IBM RESEARCH organization took interest in the problem
It was decided to use machine learning to identify the risk of developing the disease in a routine blood test at the earliest stages. Based on machine learning algorithms, researchers have discovered a way to make a significant breakthrough in the field of neurodegenerative diseases.
What have IBM Research organization achieved by using machine learning?
Experts in the field of AI took 2017 scientific data as the basis for their development. According to previous medical studies, it has been proven that the concentration of beta-amyloid (beta-amyloid peptide) in the human cerebrospinal fluid changes 10-15 years before the first strokes of Alzheimer’s disease appear. People who have an abnormal concentration of peptides are 2-3 times more likely to undergo neurodegenerative effects.
Experts from IBM Research organization decided to use machine learning in order for the AI system to analyze proteins in the blood and predict the concentration of biomarkers. Now it is not necessary to carry out expensive and complicated procedures for collecting cerebrospinal fluid or to detect the disease only after a brain scan.
IBM machine learning technology makes it possible to predict the development of Alzheimer’s disease in specific patients with an accuracy of up to 77%
It is worth noting the development is at the stages of early testing. In IBM Research confidently declare that they will continue to work in this direction and integrate AI to control of neurodegenerative diseases. But already a significant breakthrough has been made. The researchers were able to solve the problem with the late diagnosis, which is typical with Alzheimer’s. In the future, patients will not go to doctors in the later stages, when the treatment will not give visible results. With the help of machine learning and blood testing, doctors will be able to identify patients already in the early stages, which will allow them to significantly slow down the progression of the disease.
Editor of IMD News